Sculptor Capital LP purchased a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,052,467 shares of the company's stock, valued at approximately $77,443,000. Sculptor Capital LP owned approximately 0.21% of Kenvue as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Johnson Financial Group Inc. acquired a new position in Kenvue during the second quarter worth $26,000. CoreCap Advisors LLC lifted its stake in Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock valued at $29,000 after acquiring an additional 591 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Kenvue in the fourth quarter valued at $26,000. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock valued at $26,000 after acquiring an additional 618 shares during the period. Finally, MV Capital Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth about $28,000. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Stock Down 0.4%
Shares of KVUE opened at $19.34 on Wednesday. The firm has a market cap of $37.16 billion, a P/E ratio of 22.24, a price-to-earnings-growth ratio of 1.39 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $21.40. The firm's 50-day simple moving average is $19.10 and its 200 day simple moving average is $18.22.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the prior year, the firm earned $0.29 EPS. The company's revenue was up 3.0% on a year-over-year basis. On average, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Wednesday, August 12th. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is 96.55%.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on KVUE. Barclays upped their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a report on Tuesday, July 21st. Zacks Research downgraded Kenvue from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, June 15th. Wall Street Zen lowered Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, UBS Group cut their price objective on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Kenvue currently has an average rating of "Hold" and a consensus price target of $19.27.
Get Our Latest Report on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
